MEDIX, God. 26 Br. 143  •  Sponzorirani članak  •  Dermatovenerologija HR ENG

Risankizumab: IL-23 inhibitor u liječenju plak psorijazeRisankizumab: IL-23 inhibitor in the treatment of plaque psoriasis

Antoanela Čarija

Os IL-23/Th17 središnje je zbivanje u imunopatogenezi psorijaze. Risankizumab (Skyrizi) indiciran je za liječenje umjerene do teške plak psorijaze u odraslih. Risankizumab je humanizirano IgG1 monoklonsko protutijelo visokog afiniteta za p19 podjedinicu IL-23 te tako sprječava vezanje IL-23 za receptor tijekom duljega razdoblja. Uspješnost blokade IL-23 u liječenju psorijaze očituje se i visokom stopom kliničkih odgovora PASI-ja 90 i PASI-ja 100. Upravo ti ishodi bili su dio kliničkih istraživanja s risankizumabom (UltIMMa-1, UltIMMa-2, IMMhance i IMMvent), u kojima je dokazana superiorna učinkovitost u odnosu na placebo, ustekinumab i adalimumab, kao i u najnovijem istraživanju IMMerge u odnosu na sekukinumab. Risankizumab je lijek vrlo dobre sigurnosti i podnošljivosti i u navedenim ispitivanjima bez znatnih razlika u pojavi ozbiljnih nuspojava u odnosu na placebo, ustekinumab, adalimumab te sekukinumab.

Ključne riječi:
inhibitor IL-2; psorijaza; risankizumab, sigurnost, učinkovitost

Članak je dostupan u cijelosti u PDF formatu

PREUZMI PDF

The IL-23 / Th17 axis is a central development in the immunopathogenesis of psoriasis. Risankizumab (Skyrizi) is indicated for the treatment of moderate to severe plaque psoriasis in adults. Risankizumab, a humanized high-affinity IgG1 monoclonal antibody for the p19 subunit of IL-23, prevents IL-23 from binding to the receptor over an extended period of time. The success of IL-23 blockade in the treatment of psoriasis is also evident in the high clinical response rates of PASI 90 and PASI 100. These outcomes were measured in several clinical trials assessing risankizumab (UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent) and demonstrated superior efficacy over placebo, ustekinumab and adalimumab, as well as over secukinumab in the most recent IMMerge study. Risankizumab is a drug of very high safety and tolerability without significant differences in the occurrence of serious side effects compared to placebo, ustekinumab, adalimumab, and secukinumab.

Key words:
IL-23 inhibitor; psoriasis; risankizumab, effectiveness, safety